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Cholecystokinin (CCK) is a peptide hormone that is
released from the gut in response to nutrients such
as lipids to lower food intake. Here we report that
a primary increase of CCK-8, the biologically active
form of CCK, in the duodenum lowers glucose
production independent of changes in circulating
insulin levels. Furthermore, we show that duodenal
CCK-8 requires the activation of the gut CCK-A
receptor and a gut-brain-liver neuronal axis to lower
glucose production. Finally, duodenal CCK-8 fails to
lower glucose production in the early onset of high-
fat diet-induced insulin resistance. These findings
reveal a role for gut CCK that lowers glucose produc-
tion through a neuronal network and suggest that
intestinal CCK resistance may contribute to hyper-
glycemia in response to high-fat feeding.
INTRODUCTION
It is well established that entry of nutrients into the intestine can
stimulate the release of gut-peptide hormones, such as CCK,
pancreatic polypeptide, peptide YY, and glucagon-like peptide
1 (GLP-1) for the regulation of food intake (Coll et al., 2007; Cum-
mings and Overduin, 2007; Murphy and Bloom, 2006). While
each gut peptide hormone is stimulated by different nutrients,
the entry of lipids into the duodenum, the first segment of the
small intestine, can stimulate the release of CCK from the I cells
that line the mucosa of the duodenum to the surrounding areas
(Moran and Kinzig, 2004).
CCK was discovered in 1928 and is initially synthesized as a
115 amino acid prepro-CCK polypeptide, which undergoes
multiple posttranslational cleavages to generate the shortest
and the complete biologically active form CCK-8 (Chandra and
Liddle, 2007). CCK can affect various processes involved in
the digestion of nutrients, such as stimulating pancreatic secre-
tions of amylase, increasing gall bladder contractions to release
bile and delaying gastric emptying for prolonged digestion in the
stomach (Chandra and Liddle, 2007).
CCK is also sufficient and necessary for duodenal lipids to
lower food intake through a neuronal network (Cummings and
Overduin, 2007; Moran and Kinzig, 2004). There are two typesof CCK receptors: CCK-A and CCK-B receptors, which reside
in the periphery (predominantly in the gastrointestinal system)
and brain, respectively (Cummings and Overduin, 2007). The
binding of CCK to CCK-A receptors is essential in feeding control
since inhibition of CCK-A receptors negated the lipid-induced
inhibitory effects on food intake (Lieverse et al., 1994; Matzinger
et al., 2000; Schwartz et al., 1999). Furthermore, vagal afferent
fibers have been found in the lamina propria of the mucosa (Ber-
thoud and Patterson, 1996), and CCK-A receptors have been
located on capsaicin-sensitive vagal afferents (Moran et al.,
1987, 1990). Collectively, the data suggest that duodenal lipid-
induced CCK acts through a paracrine action by binding to
CCK-A receptors on the vagal afferents innervating the
duodenum to lower food intake. We here describe a novel role
of intestinal CCK that triggers a gut-brain-liver neuronal network
to control glucose production in vivo.
RESULTS
Duodenal CCK Activates CCK-A Receptors
to Lower Glucose Production
CCK is released from the duodenal mucosa and is postulated to
act at the local CCK-A receptors found in the vagal afferent fibers
that innervate the lamina propria of the mucosa to exert its bio-
logical functions (Moran et al., 1987; Berthoud and Patterson,
1996). To examine whether upper intestinal CCK activation regu-
lates glucose production (Figure 1A), we selectively activated
duodenal CCK signaling via direct intraduodenal CCK-8 admin-
istration in vivo. It is important to first note that intraduodenal
CCK-8 infusion at 20 or 60 pmol/kg/min has been previously
performed and demonstrated to affect pancreatic secretion
independent of changes in circulating CCK levels in animals
(Zabielski et al., 1995). Here we administered CCK-8 (35 pmol/
kg/min) directly into the duodenum of rats that recovered from
surgical procedures for intraduodenal and pancreatic clamp
infusion studies as previously described (Wang et al., 2008)
(Figure 1B). The clamp was used here in combination with the
tracer-dilution methodology to monitor steady-state changes
in glucose kinetics that are independent of changes in peripheral
circulating insulin levels. During the clamp studies (180–200min),
when peripheral circulating plasma insulin was maintained at
near basal levels (Table S1), intraduodenal CCK-8 significantly
increased the exogenous glucose infusion rate (Figure 1C)
required tomaintain the same glucose levels as seen in intraduo-
denal saline-infused normal rats (Table S1), indicating anCell Metabolism 10, 99–109, August 6, 2009 ª2009 Elsevier Inc. 99
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Gut CCK and Neural Control of Glucose ProductionFigure 1. Duodenal CCK Suppresses Glucose Production through CCK-A Receptors
(A) Schematic representation of the working hypothesis. CCK-8 with or without MK-329 (CCK-A receptor [CCKAR] antagonist) was infused through a duodenal
catheter. SAL, saline.
(B) Experimental procedure and clamp protocol. A duodenal catheter or venous (i.v.) and arterial catheters were implanted on day 1. On day 7, the pancreatic
clamp protocol was performed. SRIF, somatostatin.
(C and D) During the pancreatic clamp (180–200 min), intraduodenal CCK-8 (35 pmol/kg/min; n = 6) infusion increased the glucose infusion rate (C; *p < 0.05
versus SAL [n = 7]) and decreased glucose production (D; *p < 0.001 versus SAL and CCK-8 + MK-329 [n = 6]). In contrast, coinfusion with MK-329 abolished
the effects of CCK-8 on glucose infusion rate (C) and GP (D).
(E) Suppression of glucose production (GP) during the clamp period (180–200min) expressed as the percentage reduction frombasal steady state (60–90min) GP
(*p < 0.01 versus all other groups).
(F) Glucose uptake was unchanged in all groups. Intraduodenal MK-329 alone (n = 7) did not affect glucose kinetics (C–F). Values are shown as mean + SEM.enhancement of insulin sensitivity. Based on the steady-state
tracer data (180–200 min), this was due selectively to a drop in
glucose production (Figures 1D and 1E) rather than an increase
in glucose uptake (Figure 1F). In another set of rats, we per-
formed intraduodenal CCK-8 (35 pmol/kg/min) administration
for 50 min and found plasma CCK levels did not change at
50 min (2.4 ± 0.7 pM [CCK-8] versus 2.3 ± 1.4 [saline]). Portal
vein samples were then taken soon after giving anesthesia at
50 min, and we first found that CCK levels in the portal vein
(5.1 ± 0.6 pM) was 2.2-fold higher, although did not reach
statistically significance, than the plasma CCK levels obtained
in duodenal saline-infused rodents. Importantly, portal CCK
levels of duodenal CCK-8-infused rats (3.4 ± 0.6 pM) were
comparable to those found in the saline-infused rats. Thus, a
primary increase of CCK-8 in the duodenum lowers glucose
production independent of changes in circulating CCK or insulin
levels.
CCK binds to the CCK-A receptors to lower food intake and
body weight (Coll et al., 2007; Cummings and Overduin, 2007;
Moran and Kinzig, 2004; Murphy and Bloom, 2006). Further-100 Cell Metabolism 10, 99–109, August 6, 2009 ª2009 Elsevier Incmore, CCK-A receptors are mostly expressed in the gut (Corp
et al., 1993; Saito et al., 1980), indicating that CCK partly reduces
food intake via the activation of gut CCK-A receptors. To ensure
that duodenal CCK administration activates CCK-A receptors,
and evaluate whether the duodenal CCK-A receptors are
required for this potent control of gut CCK-8 on glucose produc-
tion, we coadministered CCK-A receptor inhibitor MK-329
(3.2 mg/kg.min) with CCK-8 into the duodenum (Figure 1A) to
inhibit CCK-A receptors in the gut in the presence of CCK activa-
tion. Coadministration of MK-329 with CCK-8 fully reversed the
ability of CCK-8 to increase glucose infusion rate (Figure 1C)
and lower glucose production (Figures 1D and 1E), while glucose
uptake was comparable in both groups (Figure 1F). Intraduode-
nalMK-329 alone did not affect glucose kinetics (Figures 1C–1F).
Duodenal CCK Fails to Lower Glucose Production
in CCK-A Receptor-Deficient Rats
To alternatively evaluate whether CCK-A receptors are required
for the effect of gut CCK on glucose production, we performed
the same set of experiments in the CCK-A receptor-deficient.
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Gut CCK and Neural Control of Glucose ProductionFigure 2. Duodenal CCK Suppresses Glucose Production in LETO but Not in CCK-A Receptor-Deficient OLETF Rats
(A) Schematic representation of the working hypothesis. CCK-8 or saline (SAL) was infused through a duodenal catheter.
(B) Experimental procedure and clamp protocol.
(C and D) Intraduodenal CCK-8 infusion (100 pmol/kg/min) increased the glucose infusion rate (C; *p < 0.01 versus all other groups), and decreased glucose
production rate (D; *p < 0.05 versus all other groups) in LETO rats but not in OLETF rats (LETO: SAL [n = 5], CCK-8 [n = 6]; OLETF: SAL [n = 4], CCK-8
[n = 5]). In response to intraduodenal CCK-8 infusion, OLETF rats did not have any changes in the glucose infusion rate (C), and glucose production (D).
(E) Suppression of glucose production (GP) during the clamp period (180–200 min) expressed as the percentage reduction from basal (60–90 min) GP (*p < 0.01
versus other groups).
(F) Glucose uptake was unchanged in all groups.
(G and H) Pair feeding kept the OLETF rats (n = 19) the same weight as LETO rats (n = 20). Values are shown as mean ± SEM.rats (the male Otsuka Long-Evans Tokushima fatty [OLETF] rats)
and their corresponding controls (the male Long-Evans Tokush-
ima Otsuka [LETO] rats) (Figures 2A and 2B). OLETF rats are an
outbred strain of Long-Evans rats that congenitally lack a 6847
base-pair segment of the promoter region of the gene encoding
the CCK-A receptor (Funakoshi et al., 1995). We first tested
whether duodenal CCK-8 lowers glucose production in the
LETO rats as seenwith themale SD rats (Figure 1). Intraduodenal
CCK-8 (100 pmol/kg/min) increased the glucose infusion rate
required to maintain euglycemia as compared to intraduodenal
saline-treated LETO rats (Figure 2C). This corresponds to anCinhibition of glucose production (Figures 2D and 2E). Glucose
uptake was again unchanged (Figure 2F).
When placed on a regular chow ad libitum, the CCK-A-
receptor-deficient OLETF rats are hyperphagic from birth,
glucose intolerant by week 5, obese by week 10, and diabetic
by week 24 as compared to the LETO control rats (Kawano
et al., 1992; Moran, 2008; Blumberg et al., 2006). To evaluate
whether duodenal CCK-8 regulates glucose production in
OLETF rats independent of weight gain, we pair-fed the OLETF
rats to LETO rats once we received them from Tokushima Insti-
tute, Otsuka Pharmaceutical at 4 weeks of age. The LETO ratsell Metabolism 10, 99–109, August 6, 2009 ª2009 Elsevier Inc. 101
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Gut CCK and Neural Control of Glucose ProductionFigure 3. Duodenal CCK Suppresses Glucose Production by Activating a Gut-Brain-Liver Axis
(A) Schematic representation of the working hypothesis. Duodenal CCK-8 was coinfused with tetracaine, which abolishes the ascending neuronal signal to the
hindbrain. A different group of rats was given NMDA channel inhibitor MK-801 directly into the NTS. In separate studies, duodenal CCK-8 was infused into rats
that underwent hepatic vagotomy (HVAG).
(B) Experimental procedure and clamp protocol. Stereotaxic surgeries were conducted 7 days prior to vascular and duodenal cannulations. On the other hand,
hepatic vagotomies were performed immediately before the implantation of the duodenal and vascular catheters.
(C and D) Intraduodenal CCK-8 infusion increased glucose infusion rate (C; *p < 0.01 versus other groups) and decreased glucose production (D; *p < 0.01 versus
other groups). Rats that received tetracaine, MK-801 in the NTS or HVAG failed to respond to duodenal CCK-8 to increase the glucose infusion rate and lower
glucose production (SAL [n = 5], CCK-8 [n = 6], CCK-8 + tetracaine [n = 5], CCK-8 + NTS MK-801 [n = 5], CCK-8 + HVAG [n = 6].)
(E) Suppression of glucose production (GP) during the clamp period (180–200 min) expressed as the percentage decrease from basal (60–90 min) GP (*p < 0.05
versus other groups).
(F) Glucose uptake was unchanged in all groups. Intraduodenal tetracaine (n = 7), NTS MK-801 (n = 5), or HVAG (n = 6) alone did not affect glucose kinetics
(C-F).Values are shown as mean + SEM.gained body weight (Figure 2G) and increased food intake
(Figure 2H) daily over the course of 4–8 weeks of age. The
body weight continued to increase daily after 8 weeks but rapidly
slowed down upon reaching the 10th week (Figure 2G). Daily
food intake of LETO rats reached a plateau by 8 weeks (Fig-
ure 2H). We pair fed the OLETF to the LETO rats (Figure 2H)
and were successful in achieving the same body weight in
both groups at the time of clamp studies (Figure 2G). Twelve-
week-old OLETF rats underwent the clamp studies (Figure 2B)
and, in contrast to the effects seen in LETO rats, intraduodenal
CCK-8 completely failed to increase the glucose infusion rate
(Figure 2C) and lower glucose production (Figures 2D and 2E)
as compared to intraduodenal saline-infused OLEFT rats.
Together with the results of the pharmacological loss-of-function
studies, these genetic loss-of-function experiments in CCK-A
receptor-deficient rats indicate that CCK-A receptors are
required for CCK action in the gut to lower glucose production.102 Cell Metabolism 10, 99–109, August 6, 2009 ª2009 Elsevier IncDuodenal CCK Activates a Gut-Brain-Liver Axis
to Lower Glucose Production
CCK activates CCK-A receptors found on the gut vagal afferent
neurons to signal the brain to lower food intake (Coll et al., 2007;
Cummings and Overduin, 2007; Moran and Kinzig, 2004). Here
we used three independent yet complementary approaches to
investigate whether a neuronal network involving the gut, brain,
and liver mediates the suppressive effects of gut CCK on hepatic
glucose production (Figure 3A). We first administered the anes-
thetic tetracaine into the duodenum to locally inhibit the neuro-
transmission of gut vagal afferent fibers in the presence or
absence of duodenal CCK-8. This would begin evaluating
whether a neuronal network is required for the metabolic control
of gut CCK in the preabsorptive state. Administration of intraduo-
denal tetracaine alone did not affect glucose kinetics (Figures
3C–3F) but was sufficient to fully reverse the ability of CCK-8
to increase the glucose infusion rate (Figure 3C) and to lower.
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Gut CCK and Neural Control of Glucose Productionglucose production (Figures 3D and 3E). Thus, CCK-8 triggers
a neuronal signal in the intestine to lower glucose production.
The N-methyl-D-aspartate (NMDA) receptors in the gut-recip-
ient neurons in the nucleus of the solitary tract (NTS) of the hind-
brainmediate gut signals initiated byCCK or nutrients to regulate
food intake (Badman and Flier, 2005; Cummings and Overduin,
2007; Moran and Kinzig, 2004; Murphy and Bloom, 2006). We
next tested whether NTS NMDA receptors are required for gut
CCK-induced neuronal transmission to lower glucose produc-
tion (Figure 3A). We directly infused the NMDA receptor inhibitor
MK-801 (0.03 ng/min) into the NTS to inhibit glutamatergic
neurotransmission in the NTS and alone did not affect glucose
metabolism (Figures 3C–3F). However, when CCK-8 was
concomitantly administered into the duodenum, NTS MK-801
fully reversed the ability of gut CCK to increase the glucose infu-
sion rate (Figure 3C) and lower glucose production (Figures 3D
and 3E). Finally, to evaluate whether NTS NMDA receptors relay
the signal generated by gut CCK to the liver and lower glucose
production, we repeated gut CCK-8 infusion experiments in
rats that underwent the hepatic vagal branch vagotomy to elim-
inate the neurocommunication between the brain and liver (Lam
et al., 2005, 2007). Hepatic vagotomy negated the ability of
duodenal CCK-8 to increase the glucose infusion rate (Figure 3C)
and lower glucose production (Figures 3D and 3E) during the
clamps but alone did not affect glucose kinetics (Figures 3C–
3F). Together, these data collectively indicate that the NTS relays
a signal generated by intestinal CCK signaling to the liver to
inhibit glucose production.
Duodenal CCK-A Receptors Are Required for Lipids
to Lower Glucose Production
We have recently demonstrated that duodenal lipids activate
a gut-brain-liver neuronal axis to lower glucose production and
regulate glucose homeostasis (Wang et al., 2008). Given that
intestinal lipids stimulate local release of CCK to activate the
CCK-A receptors to lower food intake, we next investigated
whether CCK-A receptors in the gut are required for the gut-lipid
control on glucose homeostasis (Figures 4A and 4B). We first
demonstrated that, consistent with the previous report (Wang
et al., 2008), intraduodenal lipids increased the glucose infusion
rate required to maintain euglycemia (Figure 4C). This corre-
sponded to an inhibition of glucose production (Figures 4D and
4E) rather than an increase in glucose uptake (Figure 4F). We
then coadministered the CCK-A receptor inhibitor MK-329 with
lipids into the duodenum and found that duodenal MK-329 fully
reversed the ability of gut lipids to increase the glucose infusion
rate (Figure 4C) and lower glucose production (Figures 4D and
4E) during the clamps. These results strengthen the role of intes-
tinal CCK control on glucose production and indicate that CCK-A
receptors are required for gut lipid-sensingmechanisms to lower
glucose production.
Pharmacological and Molecular Inhibition of CCK-A
Receptors Disrupts Glucose Homeostasis
during Refeeding
We next evaluated whether direct inhibition of gut CCK-A recep-
tors negates nutrient sensing-related mechanisms activated by
a physiological fasting-refeeding protocol to maintain glucose
homeostasis. When rats are subjected to a refeeding protocol,Cthe level of plasma glucose rises rapidly, but this elevation is
restrained due to an inhibition of hepatic gluconeogenesis
(Duran-Sandoval et al., 2005). We reason that if the activation
of the gut CCK-A receptors is required for nutrient sensing-
related mechanisms activated by refeeding to restrain glucose
production and lower plasma glucose levels, direct duodenal
CCK-A receptor blocker MK-329 administration should disrupt
glucose homeostasis during refeeding (Figure 5A).
We first subjected the rats to a 40 hr fast after 5 days of
vascular and duodenal surgeries (Figure 5A). Intraduodenal
saline administration began at time 10 min and the plasma
glucose levels were at110 mg/dl (Figure 5B). Refeeding began
at time 0min and plasma glucose levels remained the same (Fig-
ure 5B). Plasma glucose levels (Figure 5B) and cumulative food
intake (Figure 5C) rose in 10 and 20 min of refeeding for the intra-
duodenal saline-infused rats. Interestingly, intraduodenal CCK-A
receptor blocker MK-329 administration started at 10 min
significantly increased plasma glucose levels by 20 mg/dl
versus saline (Figure 5B) after 20min of refeeding in the presence
of similar cumulative food intake (Figure 5C). We repeated the
fasting-refeeding protocol in the CCK-A receptor-deficient
OLETF rats and their corresponding LETO controls (Figure 6A).
We again observed a significant increase of plasma glucose
levels by 20 mg/dl (Figure 6B) in 20 min of refeeding in OLETF
versus LETO rats. The cumulative food intake was again compa-
rable in both groups (Figure 6C). These data collectively indicate
that activation of the CCK-A receptors in the gut physiologically
regulate glucose homeostasis independent of changes in food
intake.
Duodenal CCK Fails to Lower Glucose Production
in Response to High-Fat Feeding
Intestinal lipid-sensing mechanisms fail to lower glucose
production in the early onset (3 days) of high-fat diet-induced
insulin resistance (Wang et al., 2008). It was important to test
whether duodenal CCK-8 lowers glucose production in the
same disease model (Figures 7A and 7B), since our above
studies indicate that CCK activation lies downstream of gut lipids
to activate the gut-brain-liver axis to lower glucose production in
normal rodents. Duodenal CCK-8 again increased the glucose
infusion rate (Figure 7C) and lowered glucose production
(Figures 7D and 7E) when compared to duodenal saline in rats
fed with regular chow. However, rats overfed with high-fat diet
for 3 days completely failed to respond to duodenal CCK-8 to
increase the glucose infusion rate (Figure 7C) and lower glucose
production (Figures 7D and 7E), and the rate of glucose infusion
and glucose production were comparable to those obtained with
duodenal saline-infused HFD rats (Figures 7C–7F). Thus, the
data suggest that high-fat feeding induces duodenal CCK-resis-
tance, leading to a dysregulation of glucose production.
DISCUSSION
The gut peptide hormone GLP-1 has been studied worldwide for
its potential therapeutic value to increase insulin secretion in type
2 diabetes (Drucker, 2006; Holst, 2007; Kim et al., 2008). Inter-
estingly, CCK has also been documented to stimulate insulin
release through the direct binding of its receptors in islets (Rush-
akoff et al., 1987; Morisset et al., 2003; Rasmussen et al., 1990).ell Metabolism 10, 99–109, August 6, 2009 ª2009 Elsevier Inc. 103
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Gut CCK and Neural Control of Glucose ProductionFigure 4. Duodenal CCK-A Receptor Is Required for Lipids to Lower Glucose Production
(A) Schematic representation of the working hypothesis. Lipids with or without MK-329 was infused through a duodenal catheter.
(B) Experimental procedure and clamp protocol.
(C and D) Intraduodenal lipids increased the glucose infusion rate (C, *p < 0.01 versus all other groups), and decreased GP rate (D, *p < 0.001 versus all other
groups). The coinfusion of lipids and MK-329 abolished the effects of lipids on glucose infusion rate (C) and glucose production (D) fed on a regular chow
(VEH; saline + MK-329 alone, [n = 11], lipid [n = 10], lipid + MK-329 [n = 7]).
(E) Suppression of glucose production (GP) during the clamp period (180–200 min) expressed as the percentage decrease from basal (60–90 min) GP (*p < 0.01
versus all other groups).
(F) Glucose uptake was unchanged in all groups. Values are shown as mean + SEM.In this article, we unveil a role of CCK in the intestine that lowers
glucose production in the absence of changes in peripheral
circulating plasma insulin levels. More importantly, the direct
activation of CCK-A receptors by CCK in the gut triggers a gut-
brain-liver neuronal axis to lower glucose production in normal
rodents. Furthermore, direct inhibition of gut CCK-A receptors
disrupts glucose homeostasis in a fasting/refeeding protocol.
Together with the observations that CCK-A receptor-deficient
rats develop an elevated rate of hepatic glucose production, dia-
betes, and obesity (Kawano et al., 1992; Moran, 2008; Blumberg
et al., 2006; Shiba et al., 1998), the physiological relevance of our
findings on the gut CCK neuronal control of glucose production
is strengthened. These data also highlight the critical role of gut
CCK-A receptors to maintain glucose homeostasis independent
of changes in food intake.
Our current focus is to evaluate the critical role of gut CCK/
CCK-A receptor in the neural control of glucose homeostasis.
However, given the fact that circulating CCK regulates glucose104 Cell Metabolism 10, 99–109, August 6, 2009 ª2009 Elsevier Inchomeostasis as well (Verspohl et al., 1992; Liddle et al., 1988;
Metzger and Hansen, 1983), it would be of interest to determine
whether a neuronal network is required for circulating CCK to
regulate glucose homeostasis. In combination with the recent
discoveries that circulating peptide hormones such as insulin
or leptin trigger signaling cascades in the brain to lower glucose
production and regulate glucose homeostasis (Caspi et al.,
2007; Kievit et al., 2006; Obici et al., 2002; Schwartz and Porte,
2005), we propose that the central nervous system plays a vital
role to convey peptide hormonal signals initiated in the gut or
brain to regulate hepatic glucose production and maintain
glucose homeostasis.
Our current study also indicates that duodenal CCK is required
for lipid-sensingmechanisms in the gut to lower glucose produc-
tion through a neuronal network. More importantly, duodenal
CCK-8 (like duodenal lipids [Wang et al., 2008]) failed to lower
glucose production in a model of high-fat feeding. This sug-
gests that high-fat feeding rapidly induces small intestinal.
Cell Metabolism
Gut CCK and Neural Control of Glucose ProductionFigure 5. Pharmacological Inhibition of CCK-A Receptors in the Gut Disrupts Glucose Homeostasis during Refeeding
(A) Schematic representation of experimental design. Duodenal cannulation was performed onmale SD rats (240–280 g). After 5 days of recovery, animals were
subjected to a 40 hr fast (from 5 p.m. on day 5 until 9 a.m. on day 7). Ten minutes before the completion of the forty hour fast (i.e., time 10 min of refeeding
protocol), rats were infusedwith intraduodenal-saline orMK-329. Rats were refed on regular chow ad libitum at time 0min where food intake and blood glucose
levels were monitored at 0, 10, and 20 min.
(B) At the fasting state (time 10 and 0 min), rats receiving intraduodenal-saline or MK-329 have comparable plasma glucose levels representative of fasting
animals. After 20 min of refeeding, intraduodenal MK-329 infused rats have significantly higher plasma glucose levels compared to intraduodenal-saline infused
rats.
(C) Cumulative food intakewas comparable in all groups. Intraduodenal saline (n = 7), intraduodenal MK-329 (n = 6). *p < 0.01 versus control. Values are shown as
mean + SEM.CCK-resistance, leading to a dysregulation of glucose produc-
tion and homeostasis in diet-induced obesity. To increase the
potential implications of these findings, future studies are
required to evaluate whether the ability of duodenal lipids to
stimulate local CCK release is lost in obesity and diabetes, to
finely dissect the downstream small intestinal CCK/CCK-A
receptor G protein-coupled signaling pathways (Noble et al.,
1999) that could potentially control glucose production, and to
test in a systematic fashion whether small intestinal CCK-A
receptor G protein-coupled protein signaling cascade is
impaired or even could be rescued to restore glucose homeo-
stasis in obesity and diabetes. These studies could reveal novel
signaling molecules in the duodenum to be targeted for the
restoration of glucose homeostasis in diabetes and obesity.CGastric duodenal bypass surgeries have been documented to
improve glucose tolerance independent of weight loss in both
diabetic/obese rodents and humans (Rubino, 2008). Since we
described that duodenal CCK triggers a gut-brain-liver axis to
lower glucose production in normal but fails to do so in high-
fat fed rodents, we propose that duodenal bypass surgeries
improve glucose tolerance in diabetes and obesity partly
because the surgery bypasses an acquired defect involving
duodenal CCK resistance in response to high-fat feeding. This
working hypothesis remains to be explored.
In conclusion, we have provided evidence that a selective rise
in intestinal CCK activates CCK-A receptors to trigger a gut-
brain-liver neuronal axis to lower glucose production in normal
rodents. This discovery may reveal novel sites and molecularFigure 6. Molecular Inhibition of CCK-A Receptors Disrupts Glucose Homeostasis during Refeeding
(A) Schematic representation of experimental design. LETO/OLETF rats were subjected to a 40 hr fast (from 5 p.m. on day 5 until 9 a.m. on day 7). Rats were refed
on regular chow ad libitum at time 0 min where food intake and blood glucose levels were monitored at 0, 10, and 20 min.
(B) At the fasting state (time 10 and 0 min), LETO and OLETF rats have comparable plasma glucose levels representative of fasting animals. After 20 min of
refeeding, OLETF rats have significantly higher plasma glucose levels compared to LETO rats.
(C) Cumulative food intake was comparable in all groups. LETO (n = 6), OLETF (n = 9). *p < 0.01 versus control. Values are shown as mean + SEM.ell Metabolism 10, 99–109, August 6, 2009 ª2009 Elsevier Inc. 105
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Gut CCK and Neural Control of Glucose ProductionFigure 7. Duodenal CCK Fails to Lower Glucose Production in Response to High-Fat Feeding
(A) Schematic representation of the working hypothesis. CCK-8 was infused through a duodenal catheter. RC, regular chow; HFD, high-fat diet.
(B) Experimental procedure and clamp protocol. On the fourth day, the rats were either placed on RC or a HFD.
(C and D) Intraduodenal CCK-8 increased the glucose infusion rate (C; *p < 0.01 versus control), and decreased GP rate (D; *p < 0.001 versus control) in rats fed
with regular chow. Rats that were placed on a HFD for 3 days failed to respond to intraduodenal CCK-8 infusion to increase the glucose infusion rate (C) and
glucose production (D) compared to rats fed on a regular chow. SAL (n = 6), CCK-8 + RC (n = 6), SAL + HFD (n = 4), CCK-8 + HFD (n = 5).
(E) Suppression of glucose production (GP) during the clamp period (180–200 min) expressed as the percentage decrease from basal (60–90 min) GP (*p < 0.01
versus control).
(F) Glucose uptake was unchanged in all groups. Values are shown as mean + SEM.targets to enhance gut-derived peptide hormonal signaling path-
ways to restore glucose homeostasis in diabetes and obesity.
EXPERIMENTAL PROCEDURES
Chemicals
CCK-8 (Sulfated), tetracaine, and NMDA receptor blocker MK-801 were
obtained from Sigma. CCK-A receptor antagonist MK-329 was obtained
from Tocris Bioscience. Twenty percent Intralipid was obtained from Baxter
Healthcare Corporation. Stock solution of CCK-8 and MK-801 were prepared
in saline whereas stock solutions of tetracaine and MK-329 were prepared in
dimethylsulfoxide (DMSO). All stock solutions were diluted in 0.9% NaCl to
the desired concentrations.
Animal Preparation
All the animal study protocols were reviewed and approved by the Institutional
Animal Care and Use Committee of the University Health Network.
Male Spague-Dawley Rats
We studied 9-week-old Sprague-Dawley (SD) rats (250–300 g; from Charles
River Laboratories). Rats were housed individually and maintained on a stan-106 Cell Metabolism 10, 99–109, August 6, 2009 ª2009 Elsevier Inc.dard light-dark cycle with access to rat chow and water ad libitum. The rats
were allowed to acclimatize for 5 days upon arrival, and the appropriate
surgeries were then performed.
Male LETO/OLETF Rats
Four-week-old LETO and OLETF rats were obtained as a generous gift from
Dr. Kawano (Tokushima Research Institute, Otsuka Pharmaceuticals; Tokush-
ima, Japan). Rats were housed individually andmaintained on a standard light-
dark cycle with water ad libitum. To avoid the results from being confounded
with the effects of obesity, OLETF rats were pair fed with LETO rats to prevent
the development of obesity as described (Bi et al., 2001). All LETO rats had
access to standard chow ad libitum. At 8 AM each day, body weights and
food intakes of both LETO and OLETF rats were measured to ensure that
the body weights were similar (Figures 2G and 2H). After daily food intakes
of LETO rats were measured, OLETF rats were supplied with the amount of
chow equal to the prior day’s average daily chow intake of LETO rats main-
tained on ad libitum access. The OLETF rats were pair-fed until they were
11 to 12 weeks old (280–300 g), and the appropriate surgeries were then
performed.
Duodenal and Intravenous Cannulations
We performed duodenal cannulation surgeries to insert a catheter into the
duodenum at a position approximately 2cm downstream of the pyloric
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Gut CCK and Neural Control of Glucose Productionsphincter for intraduodenal infusions (Wang et al., 2008). We also placed
indwelling catheters into the internal jugular vein and carotid artery for infusion
and blood sampling (Wang et al., 2008). Recovery from surgery wasmonitored
by measuring daily food intake and weight gain for 3 to 4 days after surgery.
Stereotaxic Surgery
For a subgroup of rats that required stereotaxic surgeries, we implanted bilat-
eral catheters targeting the nucleus of the solitary tract (NTS) a week prior to
the duodenal and vascular cannulations. The coordinates were 0.0 mm on
the occipital crest, 0.8 mm (both sides, left and right) lateral to the midline,
and 7.9 mm below the skull surface (Wang et al., 2008).
Selective Hepatic Branch Vagotomy
For another subgroup of rats which were subjected to hepatic branch
vagotomy, the surgeries were performed as previously described (Wang
et al., 2008). A laparotomy incision was made on the ventral midline, followed
by a second incision to open the abdominal muscle wall, exposing the gastro-
intestinal tract in the peritoneum. A gastrohepatic ligament was severed using
fine forceps and the stomach was gently retracted into sterile-saline soaked
cotton gauze to reveal descending esophagus and ventral subdiaphragmatic
vagal trunk. The hepatic branch of the ventral subdiaphragmatic vagal trunk
was transected by microcautery in between the two sutures, severing and
cauterizing hepatic vagus. Transecting the hepatic branch of the vagal nerve
disrupts neural communications between the liver and the brain. This also
results in a slightly decreased innervation to the intestine as there are minor
innervations of the hepatoduodenal subbranch, which supplies a small portion
of the intestine.
Clamp Procedure
Rats were restricted to 58 kcal of caloric intake the night prior to the in vivo
infusion experiments. The in vivo infusion experiments spanned a total of 200
min. At the onset of the experiment, a primed continuous infusion of [3-3H]-
glucose (bolus 40 uCi; 0.4 uCi/min) was initiated (t = 0 min) and maintained
throughout the protocol to assess glucose kinetics based on the tracer-dilution
methodology (Wang et al., 2008).
At t = 90 min, a pancreatic (basal insulin) clamp was started by providing a
continuous infusion of insulin (0.8 mU/kg/min) and somatostatin (3 mg/kg/min)
to inhibit endogenous insulin and glucagon secretions. In order to achieve
euglycemia, we also infused 25% glucose at a variable rate (adjusted every
10 min from t = 120–200 min) to maintain plasma glucose levels that are
comparable to basal (t = 6090min). For experiments that required the admin-
istration of MK-801 (Sigma, 0.03 ng/min) to the NTS, the infusion began at
t = 90 min and lasted until t = 200 min. Finally, intraduodenal (i.d.) infusions
were initiated at t = 150200min to determine the effects of different duodenal
treatments on glucose kinetics. The Harvard Apparatus PHD 2000 infusion
pumps were used for all infusions during the infusion protocol. Plasma
samples were taken at 10 min intervals to determine the specific activity of
[3-3H]-glucose between t = 6090 min (basal) and t = 180200 min (clamp)
to assess glucose kinetics. Additional blood samples were also collected at
t = 90 min (basal), and t = 180 and 200 min to determine hormone levels.
Intraduodenal Infusions and Treatments
The following substances were continuously infused to the duodenum through
the duodenal catheter at t = 150–200 min (0.01 mL/min): (1) saline, (2) CCK-8
(35 pmol/kg/min; 100 pmol/kg/min), (3) CCK-8 (35 pmol/kg/min) + tetracaine
(0.01 mg/min), (4) CCK-8 (35 pmol/kg/min) + CCK-A receptor antagonist
MK-329 (1.6 mg/kg/min; 3.2 ug/kg/min), (5) 20% Intralipids (0.03 kcal/min),
and (6) 20% Intralipids (0.03 kcal/min) + MK-329 (1.6 mg/kg/min).
For CCK-8, the infusion rate of 35 pmol/kg/min (or 1750 pmol/kg in 50 min)
was chosen based on a previous study indicating that intraduodenal CCK-8
administered at 20 or 60 pmol/kg/min stimulates pancreatic secretion in calves
independent of changes in circulating CCK levels (Zabielski et al., 1995). It is to
our knowledge that we are one of the first to test the biological function of intra-
duodenal CCK-8 in rats, but previous studies had indicated that intraperitoneal
injection of CCK-8 at 1750 pmol/kg suppressed food intake in SD rats (Ritter
and Ladenheim, 1985). Although intraduodenal administration of CCK-8 into
the lumen may result in partial degradation of CCK, we consistently observed
an inhibition of glucose production that was mediated by the activation of gut
CCK-A receptors. Thus, these findings suggest that the CCK-8 doses that
were used allow the CCK to reach pass the mucosa.CFor all experiments performed in male SD rats, we infused CCK-8 at
35 pmol/kg/min i.d., and it was shown to suppress GP potently (Figure 1). In
preliminary experiments performed in LETO rats, 35 pmol/kg/min of CCK-8
failed to suppress GP as in SD rats. A previous study demonstrated that in
the duodenum, the level of CCK-A receptor gene expression is significantly
higher in SD rats than LETO rats (Gulley et al., 2005), indicating that LETO
rats may have a lower protein expression of CCK-A receptors in the
duodenum. The potentially reduced availability of CCK-A receptors suggests
that LETO rats may be less sensitive to CCK-8 in the duodenum than SD
rats. Subsequently, we increased the dose of CCK-8 to 100 pmol/kg/min,
and it was sufficient to suppress GP in the LETO rats (Figure 2).
For i.d. intralipids, tetracaine, or NTS NMDA-receptor blocker MK-801
administrations, the infusion doses were chosen according to a previous study
(Wang et al., 2008). For the CCK-A receptor antagonist MK-329, it has been
shown previously that MK-329 given at a dose as low as 6.25 mg/kg i.p.
reversed the effect of CCK-8 on feeding (Melville et al., 1992). In our preliminary
experiments, we coinfused 35 pmol/kg/min of CCK-8 with 1.6 mg/kg/min of
MK-329 i.d. Yet, MK-329 at this dose did not abolish theGP suppression effect
of CCK-8 (GP percent suppression: 40 ± 2; n = 2). Subsequently, we doubled
the dose of MK-329 to 3.2 mg/kg/min, and the GP suppression effect of CCK-8
was abolished. The administration of 3.2 mg/kg/min of MK-329 in the
duodenum abolished the effects of CCK-8 (35 pmol/kg/min i.d., Figure 1).
On the other hand, the GP suppression effect of lipids was inhibited when
coinfused with MK-329 at 1.6 mg/kg/min (Figure 4).
Fasting-Refeeding Experiment
Five days postduodenal surgery, animals whose daily food intake and body
weight had recovered back to baseline underwent the fasting-refeeding
studies. Rats were fasted for 40 hr (fast began at 5:00 p.m. on day 5 and lasted
until 9:00 a.m. on day 7). Ten minutes before completion of the forty hour fast
(i.e., 8:30 a.m. on day 7, t = 10), rats began a continuous intraduodenal-infu-
sion of either (1) saline or (2) MK-329 (3.2 ug/kg/min). Upon completion of the
40 hr fast (i.e., 9 a.m. on day 7, t = 0), rats (including LETO andOLETF) were fed
ad libitum on regular chow diet. Blood glucose levels and food intake were
measured at t = 10, 0, 10, and 20 min.
High-Fat Feeding in Male SD Rats
A subgroup of male SD rats, with duodenal and i.v. catheters implanted, were
placed on a lard-oil enriched high-fat diet for 3 days. See Table S2 for diet
composition of regular chow and high-fat diet. Previous studies have indicated
that rats develop defects in duodenal lipid-sensingmechanisms after 3 days of
high caloric intake (Wang et al., 2008). Here, we performed pancreatic basal
insulin clamps to address whether intestinal CCK regulates GP in the early
onset of diet-induced insulin resistant rodents.
Peripheral and Portal CCK Measurements
Wedeterminedperipheral andportalCCKusingacommercially available radio-
immunoassay kit (Alpco). According to the manufacturer’s specifications,
1.0 ml of plasma is required to obtain a precise CCK measurement. Therefore,
a separate set of experiments was required to collect sufficient plasma for
the measurement of CCK. In this separate set of experiments, i.d. saline and
CCK-8were infused in SD rats with duodenal/i.v. catheters implanted, to deter-
mine whether saline or CCK-8 has any effect on peripheral and portal CCK
concentrations. Rats received either i.d. saline or CCK-8 infusion for 50 min
to mimic the protocol used in the clamp studies. At t = 50 min, plasma was
collected from the vascular catheters. The rats were then anesthetized using
ketamine (5mg i.v.), andportal bloodwasextracted fromtheportal vein. Plasma
was collected and stored in20Cuntil the radioimmunoassaywasperformed.
Biochemical Analysis
Plasma glucose concentrations were measured using the glucose oxidase
method (Glucose analyzer GM9, Analox Instruments; Lunenbertg, MA).
Plasma insulin concentrations were measured using a radioimmunoassay
(Linco Research; St. Charles, MO).
Calculations
Data are presented asmeans ± SEM. Data between t = 60–90 min and t = 180–
200 min were averaged for the basal and clamp conditions, respectively.ell Metabolism 10, 99–109, August 6, 2009 ª2009 Elsevier Inc. 107
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variance followed by Student’s t test with a probability of p < 0.05 taken as
significant.
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